Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Hemodynamic Device Helps Maintain Stable Heart Function

By HospiMedica International staff writers
Posted on 07 Apr 2015
A miniature blood pump system helps support stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures.

The Impella 2.5 System is a heart pump intended for temporary use by patients with severe symptomatic coronary artery disease (CAD) and diminished (but stable) heart function who are undergoing a HRPCI procedure (such as balloon angioplasty and stenting), but are not candidates for surgical coronary bypass treatment. More...
An interventional cardiologist first guides the Impella 2.5 into position via percutaneous angioplasty, guiding the loaded tip of the catheter through the arteries and into the left ventricle.

Throughout the procedure, the system draws blood from the left ventricle and pumps it into the aorta at rates of up to 2.5 L/min. An external controller and monitor turns the pump on and off, measures heart function, and allows healthcare providers to adjust it as necessary to maintain stable heart function and circulation during the procedure. The temporary circulatory support provided by the system allows a longer and more thorough procedure by preventing episodes of hemodynamic instability—such as poor circulation and low blood pressure—due to temporary abnormalities in heart function.

Studies have shown that complex, high-risk patients undergoing protected percutaneous coronary intervention (PCI) with Impella 2.5 support experience reduced adverse events, improved quality of life, and can return home faster. Fewer later adverse events may occur in patients undergoing HRCPI with the pump, compared to those undergoing HRPCI with an intra-aortic balloon pump (IABP). The Impella 2.5 System is a product of Abiomed (Danvers, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“As heart disease patients get sicker, more complex, and desire minimally invasive solutions, there are few options available to them to help improve their quality of life in a cost effective manner," said Michael Minogue, chairman, president, and CEO of Abiomed. “We are excited that Impella has been recognized as a device that can potentially become the new standard of care with a “first of its kind' approval.”

All patients undergoing HRPCI are at some risk for complications related to decreased heart function and lowered blood pressure during the procedure, but patients in need of treatment for extensive or critically located CAD who are already experiencing diminished heart function also face at high risk for serious complications.

Related Links:

Abiomed
Impella 2.5 CP animation



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.